{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:26:07Z","timestamp":1778657167355,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s11060-017-2575-9","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T09:42:04Z","timestamp":1501062124000},"page":"307-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A phase I\/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma"],"prefix":"10.1007","volume":"135","author":[{"given":"Sophie E. M.","family":"Veldhuijzen van Zanten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-8516","authenticated-orcid":false,"given":"Fatma E.","family":"El-Khouly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H. A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewi P.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Sanchez Aliaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis J. A.","family":"Haasbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole I.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Peter","family":"Vandertop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dannis G.","family":"van Vuurden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertjan J. L.","family":"Kaspers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,26]]},"reference":[{"key":"2575_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","volume":"7","author":"D Hargrave","year":"2006","unstructured":"Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241\u2013248. doi:\n                        10.1016\/S1470-2045(06)70615-5","journal-title":"Lancet Oncol"},{"key":"2575_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ctrv.2011.06.007","volume":"38","author":"MHA Jansen","year":"2012","unstructured":"Jansen MHA, van Vuurden DG, Vandertop WP, Kaspers GJL (2012) Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev 38:27\u201335. doi:\n                        10.1016\/j.ctrv.2011.06.007","journal-title":"Cancer Treat Rev"},{"key":"2575_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00263825","volume":"7","author":"IA Langmoen","year":"1991","unstructured":"Langmoen IA, Lundar T, Storm-Mathisen I et al (1991) Management of pediatric pontine gliomas. Childs Nerv Syst 7:13\u201315","journal-title":"Childs Nerv Syst"},{"key":"2575_CR4","doi-asserted-by":"publisher","unstructured":"Sigmond J, Honeywell RJ, Postma TJ et al (2008) Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. doi:\n                        10.1093\/annonc\/mdn543","DOI":"10.1093\/annonc\/mdn543"},{"key":"2575_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1634\/theoncologist.10-1-34","volume":"10","author":"B Pauwels","year":"2005","unstructured":"Pauwels B, Korst AEC, Lardon F, Vermorken JB (2005) Combined modality therapy of gemcitabine and radiation. Oncologist 10:34\u201351. doi:\n                        10.1634\/theoncologist.10-1-34","journal-title":"Oncologist"},{"key":"2575_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-007-9489-x","volume":"87","author":"A Fabi","year":"2008","unstructured":"Fabi A, Mirri A, Felici A et al (2008) Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. J Neurooncol 87:79\u201384. doi:\n                        10.1007\/s11060-007-9489-x","journal-title":"J Neurooncol"},{"key":"2575_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00280-009-1155-x","volume":"65","author":"G Metro","year":"2010","unstructured":"Metro G, Fabi A, Mirri MA et al (2010) Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemother Pharmacol 65:391\u2013397. doi:\n                        10.1007\/s00280-009-1155-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"2575_CR8","doi-asserted-by":"publisher","unstructured":"Steinherz PGG, Seibel NLL, Ames MMM et al (2002) Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children\u2019s Cancer Group. doi:\n                        10.1080\/1042819021000015880","DOI":"10.1080\/1042819021000015880"},{"key":"2575_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.cad.0000217426.82702.74","volume":"17","author":"A Wagner-Bohn","year":"2006","unstructured":"Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP et al (2006) Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs 17:859\u2013864. doi:\n                        10.1097\/01.cad.0000217426.82702.74","journal-title":"Anticancer Drugs"},{"key":"2575_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/pbc.20419","volume":"46","author":"AL Angiolillo","year":"2006","unstructured":"Angiolillo AL, Whitlock J, Chen Z et al (2006) Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a Children\u2019s Oncology Group Report. Pediatr Blood Cancer 46:193\u2013197. doi:\n                        10.1002\/pbc.20419","journal-title":"Pediatr Blood Cancer"},{"key":"2575_CR11","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1200\/JCO.2008.20.3778","volume":"27","author":"PD Cole","year":"2009","unstructured":"Cole PD, Schwartz CL, Drachtman RA et al (2009) Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin\u2019s disease: a children\u2019s oncology group report. J Clin Oncol 27:1456\u20131461. doi:\n                        10.1200\/JCO.2008.20.3778","journal-title":"J Clin Oncol"},{"key":"2575_CR12","unstructured":"Kinderformularium. Geneesmiddelen. Gemcitabine. \n                        https:\/\/www.kinderformularium.nl\/geneesmiddel\/2882\/gemcitabine\n                        \n                    . Accessed 5 Dec 2016"},{"key":"2575_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708\u2013720. doi:\n                        10.1093\/jnci\/djp079","journal-title":"J Natl Cancer Inst"},{"key":"2575_CR14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. U.S. Department of Health and Human Services. Published May 28, 2009 (v4.03: June 14, 2010)"},{"issue":"9","key":"2575_CR15","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3174\/ajnr.A4782","volume":"37","author":"T Jaspan","year":"2016","unstructured":"Jaspan T, Morgan PS, Warmuth-Metz M et al (2016) Response assessment in pediatric neuro-oncology: implementation and expansion of the RANO criteria in a randomized phase II trial of pediatric patients with newly diagnosed high-grade gliomas. Am J Neuroradiol 37(9):1581\u20131587","journal-title":"Am J Neuroradiol"},{"key":"2575_CR16","unstructured":"Varni JW (2016) The PedsQL\u2122 measurement model for the Pediatric Quality of Life Inventory\u2122. \n                        http:\/\/www.pedsql.org\/about_pedsql.html\n                        \n                    . Accessed 15 Nov 2016"},{"key":"2575_CR17","unstructured":"Varni JW (2016) Pediatric Quality of Life Inventory\u2122 (PedsQL\u2122). Scaling and scoring. \n                        http:\/\/www.pedsql.org\/PedsQL-Scoring.pdf\n                        \n                    . Accessed 15 Nov 2016"},{"key":"2575_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11060-016-2141-x","volume":"128","author":"SEM Veldhuijzen van Zanten","year":"2016","unstructured":"Veldhuijzen van Zanten SEM, Cruz O, Kaspers GJL et al (2016) State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature. J Neurooncol 128:387\u2013394. doi:\n                        10.1007\/s11060-016-2141-x","journal-title":"J Neurooncol"},{"key":"2575_CR19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(01)00858-5","volume":"416","author":"AM Bergman","year":"2001","unstructured":"Bergman AM, Pinedo HM, Peters GJ (2001) Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur J Pharmacol 416:19\u201324","journal-title":"Eur J Pharmacol"},{"key":"2575_CR20","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/sj.bjc.6602453","volume":"92","author":"N Gassler","year":"2005","unstructured":"Gassler N, Zhang C, Wenger T et al (2005) Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer 92:1084\u20131088. doi:\n                        10.1038\/sj.bjc.6602453","journal-title":"Br J Cancer"},{"key":"2575_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/neuonc\/nou104","volume":"17","author":"MH Jansen","year":"2015","unstructured":"Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E et al (2015) Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol 17:160\u2013166. doi:\n                        10.1093\/neuonc\/nou104","journal-title":"Neuro Oncol"},{"key":"2575_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2514-9","author":"SEM Veldhuijzen van Zanten","year":"2017","unstructured":"Veldhuijzen van Zanten SEM, Lane A, Heymans MW et al (2017) External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. J Neurooncol. doi:\n                        10.1007\/s11060-017-2514-9","journal-title":"J Neurooncol"},{"key":"2575_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1586\/14737140.2015.974563","volume":"15","author":"SEM Veldhuijzen van Zanten","year":"2015","unstructured":"Veldhuijzen van Zanten SEM, Jansen MHA, Sanchez Aliaga E et al (2015) A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Rev Anticancer Ther 15:157\u2013164. doi:\n                        10.1586\/14737140.2015.974563","journal-title":"Expert Rev Anticancer Ther"},{"key":"2575_CR24","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/1097-0142(19851001)56:7+<1804::AID-CNCR2820561316>3.0.CO;2-5","volume":"56","author":"F Epstein","year":"1985","unstructured":"Epstein F (1985) A staging system for brain stem gliomas. Cancer 56:1804\u20131806","journal-title":"Cancer"},{"key":"2575_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-006-9133-1","volume":"79","author":"S Wagner","year":"2006","unstructured":"Wagner S, Warmuth-Metz M, Emser A et al (2006) Treatment options in childhood pontine gliomas. J Neurooncol 79:281\u2013287. doi:\n                        10.1007\/s11060-006-9133-1","journal-title":"J Neurooncol"},{"key":"2575_CR26","first-page":"683","volume":"9","author":"M Vulpen Van","year":"2002","unstructured":"Van Vulpen M, Kal HB, Taphoorn MJB, El Sharouni SY (2002) Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep 9:683\u2013688","journal-title":"Oncol Rep"},{"key":"2575_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ijrobp.2015.10.032","volume":"94","author":"MM Kim","year":"2016","unstructured":"Kim MM, Camelo-Piragua S, Schipper M et al (2016) Gemcitabine plus radiation therapy for high-grade glioma: long-term results of a phase 1 dose-escalation study. Int J Radiat Oncol 94:305\u2013311. doi:\n                        10.1016\/j.ijrobp.2015.10.032","journal-title":"Int J Radiat Oncol"},{"key":"2575_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11060-016-2187-9","volume":"129","author":"BN Mandrell","year":"2016","unstructured":"Mandrell BN, Baker J, Levine D et al (2016) Children with minimal chance for cure: parent proxy of the child\u2019s health-related quality of life and the effect on parental physical and mental health during treatment. J Neurooncol 129:373\u2013381. doi:\n                        10.1007\/s11060-016-2187-9","journal-title":"J Neurooncol"}],"updated-by":[{"DOI":"10.1007\/s11060-017-2636-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000}}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-017-2575-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2575-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2575-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T11:24:47Z","timestamp":1509449087000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-017-2575-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,26]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2575"],"URL":"https:\/\/doi.org\/10.1007\/s11060-017-2575-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11060-017-2636-0","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,26]]}}}